VSL#3® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis

Liver International

Volumn 33, Issue 10, 2013, Pages 1470-1477

  Jayakumar, Saumya ^a,b   Carbonneau, Michelle ^b   Hotte, Naomi ^b   Befus, A Dean ^b   St Laurent, Chris ^c   Owen, Richard ^b   Mccarthy, Mairin ^b   Madsen, Karen ^b   Bailey, Robert J ^b   Ma, Mang ^b   Bain, Vince ^b   Rioux, Kevin ^a   Tandon, Puneeta ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NONE

Author keywords

Double blind; Hepatic venous portal gradient; Placebo controlled; Portal hypertension; Randomized

Indexed keywords

ALDOSTERONE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; PLACEBO; PROBIOTIC AGENT; RENIN; UNCLASSIFIED DRUG; VSL#3; VSL3;

ADULT; ALCOHOL LIVER CIRRHOSIS; ALDOSTERONE BLOOD LEVEL; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DOUBLE BLIND PROCEDURE; END STAGE LIVER DISEASE; FEMALE; HUMAN; MALE; MICROFLORA; OUTCOME ASSESSMENT; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL;

DOUBLE BLIND; HEPATIC VENOUS PORTAL GRADIENT; PLACEBO CONTROLLED; PORTAL HYPERTENSION; RANDOMIZED;

ALDOSTERONE; CHEMOKINES; DNA PRIMERS; FECES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PORTAL PRESSURE; PROBIOTICS; RADIOIMMUNOASSAY; RENIN; STATISTICS, NONPARAMETRIC;

EID: 84885179217     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12280     Document Type: Article

References (52)

1. Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011; 60: 1254-9.
2. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
3. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
4. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
5. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
6. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. Hepatology 1994; 26: 1372-8.
7. Garcia-Tsao G. Bacterial translocation: cause or consequence of decompensation in cirrhosis? J Hepatol 2001; 34: 150-5.
8. Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-15.
9. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-8.
10. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
11. Chin-Dusting JP, Rasaratnam B, Jennings JL, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997; 127: 985-8.
12. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-93.
13. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
14. Berg RD. Inhibition of Escherichia coli translocation from the gastrointestinal tract by normal cecal flora in gnotobiotic or antibiotic-decontaminated mice. Infect Immun 1980; 29: 1073-81.
15. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-14.
16. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-91.
17. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23: 679-92.
18. Qin HL, Shen TY, Gao ZG, et al. Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J Gastroenterol 2005; 11: 2591-6.
19. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology 2006; 130: 731-46.
20. Yan F, Cao H, Cover TL, et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132: 562-75.
21. DA Hernandez IG, Vorackova FV, Uribe M. Abnormalities in proximal small bowel motility in patients with cirrhosis. Ann Hepatol 2008; 7: 120.
22. Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination? Clin Sci 2004; 107: 425-34.
23. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277: 50959-65.
24. Tien MT, Girardin SE, Regnault B, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 2006; 176: 1228-37.
25. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804-16.
26. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.
27. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3.
28. Ewaschuk J, Endersby R, Thiel D, et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007; 46: 841-50.
29. Lata J, Novotny I, Pribramska V, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-3.
30. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74: 123-7.
31. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am J Transplant 2005; 5: 125-30.
32. Malaguarnera M, Greco F, Barone G, et al. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52: 3259-65.
33. Boca M, Vyskocil M, Mikulecky M, et al. [Complex therapy of chronic hepatic encephalopathy supplemented with probiotic: comparison of two studies]. Casopis lekaru ceskych. 2004; 143: 324-8. Komplexna liecba chronickej hepatalnej encefalopatie doplnena probiotikom. Porovnanie dvoch studii.
34. Liu Q, Duan ZP, Ha d, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9.
35. Tandon P, Moncrief K, Madsen K, et al. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 2009; 29: 1110-5.
36. Llovet JM, Bartoli R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998; 28: 307-13.
37. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 573-82.
38. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280-3.
39. Andrews CN, Griffiths TA, Kaufman J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 374-83.
40. Amon JJ, Devasia R, Xia G, et al. Molecular epidemiology of foodborne hepatitis a outbreaks in the United States, 2003. J Infect Dis 2005; 192: 1323-30.
41. Nainan OV, Armstrong GL, Han XH, et al. Hepatitis a molecular epidemiology in the United States, 1996-1997: sources of infection and implications of vaccination policy. J Infect Dis 2005; 191: 957-63.
42. Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
43. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
44. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-8.
45. Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-51.
46. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-15.
47. Morrow LE, Gogineni V, Malesker MA. Synbiotics and probiotics in the critically ill after the PROPATRIA trial. Curr Opin Clin Nutr Metabol Care 2012; 15: 147-50.
48. Kemp W, Colman J, Thompson K, et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. Liver Int 2009; 29: 427-33.
49. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-46.
50. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-8.
51. Blackwood CB, Hudleston D, Zak DR, Buyer JS. Interpreting ecological diversity indices applied to terminal restriction fragment length polymorphism data: insights from simulated microbial communities. Appl Environ Microbiol 2007; 73: 5276-83.
52. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20: 506-11.